

Michigan Pharmacy and Therapeutics Committee  
Asthma Allergy Workgroup  
April 2009

Following review and discussion, the workgroup recommends to the full committee for consideration at the June meeting the following:

Inhaled Anticholinergics

No change to current classification of the drug products

Antihistamines 2<sup>nd</sup> Generation

No change to current classification of the drug products

Beta Adrenergics Short Acting

Add ProAir HFA and Proventil HFA without prior authorization

Work on a messaging system at Point of Service to influence beneficiaries to return to their doctors when the number of prescriptions for these rescue inhalers dispensed per beneficiary exceeds a limit

Beta Adrenergics Long Acting

No change to current classification of the drug products

Beta Adrenergics for Nebulizers

No change to current classification of the drug products

Beta Adrenergic/ Corticosteroid Inhaler Combinations

No change to current classification of the drug products

Inhaled Glucocorticoids

Add Alvesco and Pulmicort flexihaler without prior authorization

Construct a Drug Utilization Review project to identify patients receiving BID dosing of Pulmicort nebulizer solution, and review if QD dosing of a higher amount is suitable for the patient

Leukotriene Inhibitors

No change to current classification of the drug products

Nasal Steroids

Require prior authorization on Nasacort AQ

In addition, the workgroup reviewed a new class of drugs, Nasal Antihistamines for inclusion as a PDL class.

The workgroup recommends the following

**Nasal Antihistamines**

**Astelin**

**Astepro**

Requires Prior Authorization

Patanase